<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Solid Biosciences Inc. — News on 6ix</title>
<link>https://6ix.com/company/solid-biosciences-llc</link>
<description>Latest news and press releases for Solid Biosciences Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/solid-biosciences-llc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c06078dffbe2df118778.webp</url>
<title>Solid Biosciences Inc.</title>
<link>https://6ix.com/company/solid-biosciences-llc</link>
</image>
<item>
<title>Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-to-showcase-a-large-presence-at-the-29th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-to-showcase-a-large-presence-at-the-29th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy</guid>
<pubDate>Thu, 30 Apr 2026 12:00:00 GMT</pubDate>
<description>- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that multiple abstracts have been accepted for presentation at the upcoming 29th Annual Meeting of the American Society of G</description>
</item>
<item>
<title>Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-receipt-of-european-commission-orphan-drug-designation-for-sgt-003-for-the-treatment-of-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-receipt-of-european-commission-orphan-drug-designation-for-sgt-003-for-the-treatment-of-duchenne-muscular-dystrophy</guid>
<pubDate>Tue, 28 Apr 2026 04:00:00 GMT</pubDate>
<description>- Orphan drug designation from the European Commission underscores Solid’s commitment to advance SGT-003 through a global development effort for individuals</description>
</item>
<item>
<title>Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical,</description>
</item>
<item>
<title>Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-provides-interim-positive-clinical-update-on-phase-12-inspire-duchenne-trial</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-provides-interim-positive-clinical-update-on-phase-12-inspire-duchenne-trial</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic</description>
</item>
<item>
<title>Solid Biosciences Announces Oversubscribed $240 Million Private Placement</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-oversubscribed-dollar240-million-private-placement-34</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-oversubscribed-dollar240-million-private-placement-34</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines</description>
</item>
<item>
<title>Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-positive-feedback-130000148</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-positive-feedback-130000148</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for additional meetings with the FDA in 1H 2026 to align on a potential accelerated approval pathway for SGT-003 - - INSPIRE DUCHENNE: SGT-003 continues to be generally well tolerated with 36 participants dosed as of February 9, 2026, in Phase 1/2 trial - CHARLESTOWN, Mass., Feb. 09, 2026 (GL</description>
</item>
<item>
<title>Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-present-guggenheim-emerging-130000445</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-present-guggenheim-emerging-130000445</guid>
<pubDate>Fri, 06 Feb 2026 13:00:00 GMT</pubDate>
<description>CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:30 AM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Compan</description>
</item>
<item>
<title>Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-provides-2026-outlook-211500863</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-provides-2026-outlook-211500863</guid>
<pubDate>Tue, 13 Jan 2026 21:15:00 GMT</pubDate>
<description>- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - Duchenne: First participant enrolled in IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled, ex-U.S. clinical trial, with dosing expected in Q1 2026 - - FA: First participant dosed in Phase 1b FALCON clinical trial; FDA Orphan Drug designation granted to SGT-212</description>
</item>
<item>
<title>Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-receives-fda-orphan-211500040</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-receives-fda-orphan-211500040</guid>
<pubDate>Mon, 12 Jan 2026 21:15:00 GMT</pubDate>
<description>- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026, subject to participant enrollment - CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that U.S.</description>
</item>
<item>
<title>Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-doses-first-participant-130500094</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-doses-first-participant-130500094</guid>
<pubDate>Mon, 12 Jan 2026 13:05:00 GMT</pubDate>
<description>Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollmentCHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-human clinical trial evaluating SGT-212, its investigational gene therapy for</description>
</item>
<item>
<title>Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-present-44th-annual-130000082</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-present-44th-annual-130000082</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>CHARLESTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT (8:15 p.m. ET). A live webcast of the presentation will be available on the Events page of the Investors section of</description>
</item>
<item>
<title>Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-reports-inducement-grants-211500267</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-reports-inducement-grants-211500267</guid>
<pubDate>Mon, 05 Jan 2026 21:15:00 GMT</pubDate>
<description>CHARLESTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 7,000 restricted stock units (“RSUs”) to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable e</description>
</item>
<item>
<title>Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-duchenne-muscular-215100154</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-duchenne-muscular-215100154</guid>
<pubDate>Tue, 16 Dec 2025 21:51:00 GMT</pubDate>
<description>CHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today shared that the U.S. Department of Health and Human Services (HHS) officially added Duchenne muscular dystrophy (Duchenne) to the Recommended Uniform Screening Panel (RUSP), the list of conditions recommended for universal newborn screening across the United States. For</description>
</item>
<item>
<title>Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-showcase-proprietary-next-130000729</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-showcase-proprietary-next-130000729</guid>
<pubDate>Mon, 08 Dec 2025 13:00:00 GMT</pubDate>
<description>CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it will present data from its next-generation, proprietary capsid AAV-SLB101 and its cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025, in Washington, D.C. Gabriel Brooks, M.D., Soli</description>
</item>
<item>
<title>Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-receives-fda-rare-130000301</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-receives-fda-rare-130000301</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – – FALCON Phase 1b clinical trial participant screening underway – CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it received Ra</description>
</item>
<item>
<title>Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-licensing-agreement-130000832</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-announces-licensing-agreement-130000832</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>- Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) -- AAV-SLB101 has been generally well tolerated in the 23 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of a safety cutoff of October 31, 2025 - - Solid continues to expand collaborative efforts for AAV-SLB101 with over 30 agreements including licenses executed -</description>
</item>
<item>
<title>Solid Biosciences to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-participate-upcoming-investor-130000109</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-participate-upcoming-investor-130000109</guid>
<pubDate>Tue, 11 Nov 2025 13:00:00 GMT</pubDate>
<description>CHARLESTOWN, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Jefferies Global Healthcare Conference in LondonBo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will participate in a fireside chat on Tuesday, November 18, 2025, at 11:00 a.m. GMT</description>
</item>
<item>
<title>Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-awarded-innovation-passport-130000727</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-awarded-innovation-passport-130000727</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - - New Innovative Licensing and Access Pathway (ILAP) designation provides unique, end-to-end regulatory access pathway for Solid to work directly with the UK’s National Health System (NHS), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and health technology assessment (HTA) bodies: the National Institute for Health and Care Excellence (NICE),</description>
</item>
<item>
<title>Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-reports-third-quarter-210500251</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-reports-third-quarter-210500251</guid>
<pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
<description>- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with the FDA to discuss potential registrational pathways in H1 2026 - - SGT-003 has been generally well tolerated using a steroid-only prophylactic immunomodulation regimen; cardiac safety monitoring continued to show reduction in cardiac injury and early signals of cardiac function normalization - - Da</description>
</item>
<item>
<title>Solid Biosciences to Present at Upcoming Scientific Meetings</title>
<link>https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-present-upcoming-scientific-120000645</link>
<guid isPermaLink="true">https://6ix.com/company/solid-biosciences-llc/news/solid-biosciences-present-upcoming-scientific-120000645</guid>
<pubDate>Wed, 01 Oct 2025 12:00:00 GMT</pubDate>
<description>CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from its neuromuscular and cardiac programs at the World Muscle Society (WMS) 2025 Annual International Congress, October 7-11, 2025, in Vienna, Austria, and at the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual Congress, October 7-12, 2025, in Seville, Spain. “Our present</description>
</item>
</channel>
</rss>